Zimbabwe has declined a substantial American health deal worth 367 million US dollars (£272m) over five years due to the United States' request for confidential biological samples.
This rejection became public after a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesperson has since clarified that the US was demanding access to biological samples for research and profit while refused to share the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for further talks to secure a agreement suitable to both sides so the country's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a similar situation in Kenya, where a court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
According to reports, Sixteen African countries have to date signed these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data for a long time, without any corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our country would supply the basic resources for medical research with no assurance that the final treatments would be available to our population if a future health crisis arise."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending systems previously established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This framework is intended to guarantee that when a country provides its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further discussions with our US partners on how subsequent collaboration could be structured in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
A leading public health body stated it acknowledged the official position, but suggested that negotiations should continue since much of the country's Aids initiatives depended on foreign aid.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," it added.
The situation highlights the ongoing debate between receiving crucial foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.